NeOnc Technologies Finalizes All Contingencies for $50 Million Strategic Partnership with Quazar Investment as NuroMENA Holdings Receives ADGM Incorporation
NeOnc Technologies (NASDAQ: NTHI), a multi-Phase 2 clinical-stage biotech company, has completed all contingencies for a $50 million strategic partnership with Quazar Investment following the incorporation of NuroMENA Holdings Ltd. by the Abu Dhabi Global Market (ADGM).
The partnership involves Quazar Investment taking majority control of NuroMENA Holdings, which will serve as NeOnc's UAE-based subsidiary overseeing regional clinical operations in the Middle East and North Africa. The collaboration aims to accelerate the development of NeOnc's CNS therapeutic pipeline, including the NEO212 and NEO100 clinical programs for brain cancer treatment.
Quazar Investment, managing over $3.3 billion in assets, will provide strategic support to expand NeOnc's CNS platform across the MENA region, with joint governance oversight between both companies.
NeOnc Technologies (NASDAQ: NTHI), azienda biotech in fase clinica con più studi di Fase 2, ha soddisfatto tutte le condizioni per una partnership strategica da 50 milioni di dollari con Quazar Investment, a seguito dell'incorporazione di NuroMENA Holdings Ltd. da parte dell'Abu Dhabi Global Market (ADGM).
La partnership prevede che Quazar Investment acquisisca la maggioranza di NuroMENA Holdings, che fungerà da controllata di NeOnc con sede negli Emirati Arabi Uniti e coordinerà le operazioni cliniche regionali in Medio Oriente e Nord Africa. La collaborazione mira ad accelerare lo sviluppo del pipeline terapeutico per il sistema nervoso centrale (CNS) di NeOnc, inclusi i programmi clinici NEO212 e NEO100 per il trattamento dei tumori cerebrali.
Quazar Investment, che gestisce oltre 3,3 miliardi di dollari in asset, fornirà supporto strategico per espandere la piattaforma CNS di NeOnc nella regione MENA, con una governance condivisa tra le due società.
NeOnc Technologies (NASDAQ: NTHI), una compañía biotecnológica en fase clínica con múltiples ensayos de Fase 2, ha completado todas las condiciones para una asociación estratégica de 50 millones de dólares con Quazar Investment tras la constitución de NuroMENA Holdings Ltd. por parte del Abu Dhabi Global Market (ADGM).
La asociación contempla que Quazar Investment tome el control mayoritario de NuroMENA Holdings, que actuará como filial de NeOnc con sede en los Emiratos Árabes Unidos y coordinará las operaciones clínicas regionales en Oriente Medio y Norte de África. La colaboración tiene como objetivo acelerar el desarrollo de la cartera terapéutica para el sistema nervioso central (SNC) de NeOnc, incluidos los programas clínicos NEO212 y NEO100 para el tratamiento del cáncer cerebral.
Quazar Investment, que gestiona más de 3.300 millones de dólares en activos, aportará apoyo estratégico para ampliar la plataforma de SNC de NeOnc en la región MENA, con una gobernanza conjunta entre ambas compañías.
NeOnc Technologies (NASDAQ: NTHI)는 다수의 2상 임상을 진행 중인 임상 단계 바이오기업으로, 아부다비 글로벌 마켓(ADGM)이 NuroMENA Holdings Ltd.를 설립한 후 Quazar Investment와의 5,000만 달러 규모 전략적 파트너십을 위한 모든 조건을 충족했습니다.
이번 파트너십에 따라 Quazar Investment는 NuroMENA Holdings의 과반 지분을 확보할 예정이며, 해당 법인은 NeOnc의 아랍에미리트연합(UAE) 기반 자회사로서 중동 및 북아프리카(MENA) 지역의 임상 운영을 총괄하게 됩니다. 양측의 협력은 뇌암 치료를 위한 NEO212 및 NEO100 임상 프로그램을 포함한 NeOnc의 중추신경계(CNS) 치료제 파이프라인 개발을 가속화하는 것을 목표로 합니다.
33억 달러 이상의 자산을 운용하는 Quazar Investment는 MENA 지역 전역에서 NeOnc의 CNS 플랫폼 확장을 위한 전략적 지원을 제공하며, 양사가 공동 거버넌스 체계를 통해 감독할 예정입니다.
NeOnc Technologies (NASDAQ: NTHI), une société biotechnologique en phase clinique avec plusieurs essais de Phase 2, a rempli toutes les conditions pour un partenariat stratégique de 50 millions de dollars avec Quazar Investment suite à l'incorporation de NuroMENA Holdings Ltd. par l'Abu Dhabi Global Market (ADGM).
Ce partenariat prévoit que Quazar Investment acquière la majorité de NuroMENA Holdings, qui servira de filiale de NeOnc basée aux Émirats arabes unis et supervisera les opérations cliniques régionales au Moyen‑Orient et en Afrique du Nord. La collaboration vise à accélérer le développement du portefeuille thérapeutique du système nerveux central (SNC) de NeOnc, incluant les programmes cliniques NEO212 et NEO100 pour le traitement des cancers du cerveau.
Quazar Investment, qui gère plus de 3,3 milliards de dollars d'actifs, apportera un soutien stratégique pour étendre la plateforme SNC de NeOnc dans la région MENA, avec une supervision de gouvernance conjointe entre les deux sociétés.
NeOnc Technologies (NASDAQ: NTHI), ein biotechnologisches Unternehmen in klinischer Phase mit mehreren Phase‑2‑Studien, hat alle Voraussetzungen für eine strategische Partnerschaft in Höhe von 50 Millionen US‑Dollar mit Quazar Investment erfüllt, nachdem NuroMENA Holdings Ltd. beim Abu Dhabi Global Market (ADGM) eingetragen wurde.
Die Partnerschaft sieht vor, dass Quazar Investment die Mehrheitsbeteiligung an NuroMENA Holdings übernimmt, die als in den VAE ansässige Tochtergesellschaft von NeOnc die regionalen klinischen Aktivitäten im Nahen Osten und Nordafrika (MENA) steuern wird. Die Zusammenarbeit zielt darauf ab, die Entwicklung des CNS‑Therapieportfolios von NeOnc zu beschleunigen, einschließlich der klinischen Programme NEO212 und NEO100 zur Behandlung von Hirntumoren.
Quazar Investment, das über mehr als 3,3 Milliarden US‑Dollar an Vermögenswerten verwaltet, wird strategische Unterstützung leisten, um NeOncs CNS‑Plattform in der MENA‑Region auszubauen, wobei beide Unternehmen eine gemeinsame Governance‑Aufsicht übernehmen.
- Secured substantial $50 million strategic investment from Quazar Investment
- Partnership with Quazar ($3.3B AUM) provides strong financial backing and regional expertise
- Successful incorporation in ADGM enables regional expansion in MENA markets
- Strategic majority control structure established with joint governance oversight
- Dilution of control as Quazar Investment will have majority ownership of NuroMENA Holdings
- Execution risks in expanding operations to new geographic markets
Insights
NeOnc secures $50M Quazar investment and establishes UAE subsidiary, enabling regional expansion and accelerated clinical programs.
NeOnc Technologies has reached a critical milestone with the official incorporation of NuroMENA Holdings in Abu Dhabi, fulfilling all contingencies for the
The partnership's structure is particularly noteworthy - Quazar will gain majority control of NuroMENA following the investment closing, while maintaining joint governance with NeOnc. This arrangement provides NeOnc with both substantial funding and strategic regional access while allowing Quazar to secure controlling interest in a promising biotechnology platform. For NeOnc, this represents a crucial validation of its technology from a
The deal focuses on expanding NeOnc's CNS platform across the Middle East and North Africa (MENA) region, which typically lacks advanced biotechnology infrastructure but offers significant market potential. The capital will also accelerate development of NeOnc's clinical programs NEO212 and NEO100, potentially advancing these assets through their current Phase 2 stages more rapidly.
This transaction demonstrates a growing trend of Middle Eastern sovereign-backed investment vehicles seeking biotechnology assets and expertise to diversify economies and build regional healthcare capabilities. For NeOnc shareholders, this deal provides meaningful capital without a traditional dilutive financing, while establishing a pathway to commercialization in emerging markets that might otherwise be inaccessible.
Quazar Chairman and Executive Team with NeOnc’s Executive’s and Directors at Quazar’s Headquarters in Dubai.
CALABASAS, Calif. and ABU DHABI, United Arab Emirates, Aug. 11, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a multi–Phase 2 clinical-stage biotechnology company pioneering therapies for central nervous system (CNS) cancers, announced today the official incorporation of NuroMENA Holdings Ltd. by the Abu Dhabi Global Market (ADGM). With this regulatory milestone completed, all contingencies have now been met to finalize the previously announced
This strategic partnership will support the launch of NeOnc’s innovative CNS platform across the MENA region and help to accelerate development of its therapeutic pipeline, including the NEO212 and NEO100 clinical programs.
“We view this as a defining moment for NeOnc and a major validation of our global vision,” said Amir Heshmatpour, Executive Chairman and President of NeOnc Technologies. “With the finalization of NuroMENA’s incorporation and the support of Quazar Investment, we are now fully equipped ot continue our goals toward delivering life-saving therapies to a region in urgent need of innovation. This partnership not only brings capital it brings conviction, commitment, and alignment on purpose.”
Waleed K. Al Ali, Chairman and CEO of Quazar Investment, added: “We are proud to partner with NeOnc to bring cutting edge biotechnology to the UAE and beyond. With NuroMENA now officially formed under ADGM, we are positioned to assist NeOnc with efforts to transform the landscape of brain cancer and CNS treatment across the region. This is just the beginning.”
About NuroMENA Holdings Ltd.
NuroMENA is a UAE-based subsidiary of NeOnc Technologies Holdings, Inc., established as part of the UAE structure to oversee regional clinical operations, partnerships, and innovation in the Middle East and North Africa. Upon closing of the
About NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI)
NeOnc Technologies is a multi–Phase 2 clinical-stage biotechnology company focused on novel therapies for brain cancer and other CNS disorders. With a robust IP portfolio and strong academic collaborations, NeOnc is committed to transforming outcomes in one of the hardest-to-treat areas of oncology.
About Quazar Investment
Quazar Investment is a leading strategic investment firm headquartered in Abu Dhabi, managing over
“NEO100” and NEO “212” are registered trademarks of NeOnc Technologies Holdings, Inc.
Company Contact:
info@neonc.com
Investor Contact:
James Carbonara
Hayden IR
(646)-755-7412
James@haydenir.com
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/6522c372-115c-4a62-a755-8faa7119124f
FAQ
What is the value of the strategic partnership between NeOnc Technologies (NTHI) and Quazar Investment?
What is NuroMENA Holdings and how does it relate to NeOnc Technologies (NTHI)?
Who will control NuroMENA Holdings after the investment?
What therapeutic programs will the NTHI-Quazar partnership accelerate?
How large is Quazar Investment as a strategic partner for NTHI?
